设为首页         

资讯内容 Content

[ESC2009]ACCOMPLISH研究的应用及单片复方制剂(SPC)在高血压治疗中的地位--Weber教授专访
国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

 编辑:国际循环网 时间:2009/9/3 18:26:00    加入收藏
 关键字:ACCOMPLISH 单片复方制剂 倍博特 阿利吉仑 


International Circulation:  That last part you mentioned seems relevant since this is a Chinese publication.  As a journal from China with a predominantly Asian readership, it is of importance that we can apply this combination therapy to Asian populations such as in China, Japan, or other Asian countries. 

国际循环:刚刚提到的似乎与中国有关。这种联合疗法能否应用到中国、日本等亚洲人群?

Michael Weber:  Our experience would fit very well in the Asian countries, China, Japan, Korea, and so forth.  What is very interesting is that, I believe, for many patients in those countries the use of amlodipine, for example, has already been shown to be very beneficial in a number of important outcome studies.  So the combination with a blocker of the renin/angiotensin system and, I suspect, it is going to be more the use of a renin/angiotensin receptor blocker rather than an ACE inhibitor because the renin/angiotensin receptor blockers do not have the problem of cough that is so common among Asian patients taking ACE inhibitors.  I suspect the combination of a renin/angiotensin receptor blocker plus amlodipine is going to be very popular in China, Japan, and other Asian countries. 

Michael Weber教授:该试验结果完全适用于亚洲国家,如中国、日本、韩国等。已证实,氨氯地平对这些地区患者有益。与肾素/血管紧张素系统阻断剂联合将比与ACE抑制剂联合更普遍有效,因为它没有服用ACE抑制剂造成的咳嗽现象。我认为,肾素/血管紧张素系统阻断剂联合氨氯地平将推广于中国、日本和其他亚洲国家。



上一页  [1]  [2]  [3]  [4]  [5]  

   评论发言          
 
京ICP备15014970号-5   国际循环 版权所有  2008-2022 icirculation.com  All Rights Reserved